Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06072807 · ClinicalTrials.gov registry record · Phase 4
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
A Phase 4 study of Breast Cancer and Brain Metastases, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06072807 is a Phase 4 study of Breast Cancer and Brain Metastases that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 20 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06072807, a Phase 4 study of Breast Cancer and Brain Metastases, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this interventional study is to optimize the protocol of FES PET/CT in Estrogen Receptor positive Breast cancer patients with Brain metastases. Patients will undergo MRI of the brain and FDG PET/CT brain as part of standard of care for radiation treatment planning. An additional 18F-FES PET/CT brain scan will be completed before this standard of care radiation treatment. Patients will be followed prospectively with clinical and MRI assessments per standard-of-care for a total of 12 months. Study Population: Patients with ER-positive breast cancer with biopsy proven or suspected new or recurrent brain metastases (based on standard of care MRI) planned for radiation treatment of brain lesions.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Brain Imaging with 18F-FES
Study Locations (1)
New York
- New York-Presbyterian/Weill Cornell Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-12-27 |
| Est. Completion | 2027-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06072807
The ClinicalTrials.gov registry entry for NCT06072807 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Brain Imaging with 18F-FES is the first listed.
NCT06072807 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06072807 about?
NCT06072807 is a clinical study titled "Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer". The goal of this interventional study is to optimize the protocol of FES PET/CT in Estrogen Receptor positive Breast cancer patients with Brain metastases. Patients will undergo MRI of the brain and FDG PET/CT brain as part of standard of care for radiation treatment planning. An additional 18F-FES ...
What is the current status of trial NCT06072807?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2023-12-27. Estimated completion is 2027-12.
What conditions does trial NCT06072807 study?
This clinical trial studies the following conditions: Breast Cancer, Brain Metastases.
What interventions are being tested in trial NCT06072807?
The interventions under investigation include: Brain Imaging with 18F-FES (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06072807?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06072807 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies
RECRUITING · Phase 4
-
Role of TXA in Patients Undergoing Breast Free Flap Reconstruction
RECRUITING · Phase 4
-
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
RECRUITING · Phase 4
-
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
RECRUITING · Phase 4
-
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
RECRUITING · Phase 4
-
Post-mastectomy Recovery: Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.